Natalie S. Callander

Apr 21, 2024 | nature.com | Natalie S. Callander |Jonathan Kaufman |Jacob P. Laubach |Timothy Schmidt |Brandi N. Reeves |Binod Dhakal | +8 more

AbstractIn the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).

Aug 8, 2023 | onclive.com | Joshua Richter |Susan Bal |Natalie S. Callander |Alfred Garfall

Multiple Myeloma: Unmet Needs and Future Directions in CareAfter discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

Aug 8, 2023 | onclive.com | Joshua Richter |Susan Bal |Natalie S. Callander |Alfred Garfall

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Aug 1, 2023 | onclive.com | Joshua Richter |Susan Bal |Natalie S. Callander |Alfred Garfall

Several Research Avenues Are Available for Improving Response to Immunotherapy in Advanced NSCLC

Aug 1, 2023 | onclive.com | Joshua Richter |Susan Bal |Natalie S. Callander |Alfred Garfall

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.